세계의 안티센스 및 RNAi 치료제 시장 : 기술별, 용도별, 투여 경로별, 지역별
Global Antisense & RNAi Therapeutics Market, By Technology, By Application, By Route of Administration, By Geography
상품코드
:
1705804
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
안티센스 RNAi 치료제 세계 시장은 2025년 75억 9,000만 달러, 2032년에는 208억 2,000만 달러에 달하고, 2025-2032년 연평균 성장률(CAGR)은 15.5%를 보일 것으로 예측됩니다.
| 보고 범위 |
보고서 상세 내용 |
| 기준 연도 |
2024년 |
2025년 시장 규모 |
75억 9,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간(2025-2032년) CAGR |
15.50% |
2032년 가치 예측 |
208억 2,000만 달러 |
그림. 2025년 지역별 안티센스 및 RNAi 치료제 세계 시장 점유율(%)
안티센스 RNAi 치료제는 자연계에 존재하는 과정을 이용하여 특정 유전자를 표적으로 삼아 그 발현을 억제하는 약제군을 말합니다. 이들은 mRNA나 유전체 DNA에 높은 특이성으로 결합하여 작용합니다. 이를 통해 질병 관련 단백질의 발현을 억제합니다. 안티센스 RNAi 치료제 시장은 높은 특이성과 적은 부작용으로 다양한 질병을 치료할 수 있는 가능성으로 인해 크게 성장하고 있습니다. 여기에는 바이러스 감염, 암, 유전성 질환 등이 포함됩니다. 많은 신약 후보물질이 임상시험을 진행 중이기 때문에 시장은 연구개발에 많은 투자를 하고 있습니다. 또한, 신규 약물전달기술의 개발로 안티센스 RNAi 치료제의 가능성이 확대되어 지금까지 치료가 불가능했던 질병에 대한 적용이 기대되고 있습니다.
시장 역학:
안티센스 RNAi 치료제는 질병을 유발하는 유전자의 발현을 억제하도록 설계된 신규 핵산 기반 치료제로, mRNA 전사체에 결합하여 번역을 억제하거나 mRNA의 분해를 유도하는 방식으로 작용합니다. 따라서 불필요한 유전자를 선택적으로 침묵시킴으로써 다양한 유전성 질환, 암, 바이러스 감염증의 치료에 유망합니다. 이 기술은 DNA, RNA 또는 표적 mRNA에 상보적인 변형형 등 짧은 합성 핵산 사슬을 이용합니다. 세계 안티센스 RNAi 치료제 시장은 다양한 암, 유전성 질환, 감염성 질환의 전 세계 유병률 증가에 의해 주도되고 있으며, RNA 표적 치료제는 다양한 질환에 대한 임상시험에서 안전성과 유효성이 입증되어 시장 성장을 견인하고 있습니다. 또한, 나노입자와 같은 핵산 약물 전달 시스템의 지속적인 발전은 이러한 치료제의 세포 내 흡수를 촉진하여 임상 적용이 확대되고 있습니다. 그러나 약물 개발에 따른 높은 연구개발비용과 잠재적인 표적 외 작용은 시장 관계자들이 직면한 과제 중 하나입니다. 한편, 주요 브랜드의 특허 만료가 임박함에 따라 제네릭 의약품이 등장할 수 있는 기회도 있을 것으로 보입니다. 또한, 만성질환을 타겟으로 하는 새로운 RNAi 의약품 플랫폼의 개발은 시장 확대를 더욱 촉진할 것으로 보입니다.
본 조사의 주요 특징
- 세계의 안티센스 RNAi 치료제 시장을 상세하게 분석하여 2024년을 기준 연도로 하여 2025-2032년까지의 예측 기간 시장 규모와 연평균 성장률(CAGR)을 조사 분석하여 전해드립니다.
- 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 안티센스 RNAi 치료제 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등의 파라미터를 기준으로 정리하여 수록하였습니다.
- 이들 기업은 규제 약물의 연구개발, 제조, 유통에 종사하고 있습니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 안티센스 RNAi 치료제 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 안티센스 RNAi 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- Coherent Opportunity Map(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 미개척 신흥 시장
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- PORTER 분석
- 인수합병(M&A) 시나리오
제4장 안티센스 및 RNAi 치료제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
제5장 안티센스 및 RNAi 치료제 시장, 기술별, 2020년-2032년
제6장 안티센스 및 RNAi 치료제 시장, 용도별, 2020년-2032년
- 유전성 질환
- 암
- 감염증
- 신경퇴행성 질환
- 심장 대사 및 신장 질환
- 안질환
- 호흡기질환
- 피부질환
- 기타
제7장 안티센스 및 RNAi 치료제 시장, 투여 경로별, 2020년-2032년
제8장 안티센스 및 RNAi 치료제 시장, 지역별, 2020년-2032년
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제9장 경쟁 구도
- Benitec Biopharma Inc.
- Silence Therapeutics
- Ionis Pharmaceuticals, Inc
- Bio-Path Holdings Inc.
- Percheron Therapeutics Limited
- GSK plc
- Olix Pharmaceuticals, Inc.
- Sanofi
- Alnylam Pharmaceuticals, Inc.
- Arbutus Biopharma
제10장 섹션
LSH
영문 목차
Global Antisense & RNAi Therapeutics Market is estimated to be valued at USD 7.59 Bn in 2025 and is expected to reach USD 20.82 Bn by 2032, growing at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 7.59 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
15.50% |
2032 Value Projection: |
USD 20.82 Bn |
Figure. Global Antisense & RNAi Therapeutics Market Share (%), By Region 2025
Antisense & RNAi therapeutics refer to a class of drugs that use naturally occurring processes to target and inhibit the expression of specific genes. They work by binding to mRNA or genomic DNA with high specificity. This inhibits the expression of disease-associated proteins. The antisense & RNAi therapeutics market is growing substantially due to its potential to treat various conditions with high specificity and few side effects. These include viral infections, cancers, genetic disorders, and others. The market is witnessing significant investments in R&D as many drug candidates are progressing through clinical trials. The development of novel drug delivery techniques is also extending the potential of antisense & RNAi therapeutics to target previously undruggable diseases.
Market Dynamics:
Antisense and RNAi therapeutics are novel nucleic acid-based therapeutics designed to inhibit the expression of disease-causing genes. They work by binding to mRNA transcripts, preventing translation, or inducing mRNA degradation. This offers promise for treating various genetic disorders, cancers, and viral infections by selectively silencing unwanted genes. The technology utilizes short synthetic strands of nucleic acids such as DNA, RNA, or modified versions that are complementary to the target mRNA. The global antisense & RNAi therapeutics market is driven by the growing prevalence of various cancers, genetic disorders, and infectious diseases worldwide. RNA-targeting drugs have demonstrated safety and efficacy in clinical trials for various conditions, boosting market growth. Moreover, continuous advancements in nucleotide drug delivery systems, such as nanoparticles, have enhanced intracellular uptake of these therapeutics, expanding their clinical applications. However, high research and development costs associated with drug development and potential off-target effects are some of the challenges faced by market players. Meanwhile, the upcoming patent expiries of major brands will provide opportunities for generic versions. In addition, the development of novel RNAi drug platforms targeting chronic diseases will further stimulate market expansion.
Key features of the study:
- This report provides in-depth analysis of the global antisense & RNAi therapeutics market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global antisense & RNAi therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc, Bio-Path Holdings Inc., Percheron Therapeutics Limited, GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc. and Arbutus Biopharma.
- These companies are involved in the research, development, manufacturing, and distribution of controlled substances
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global antisense & RNAi therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antisense & RNAi therapeutics market
Detailed Segmentation:
- By Technology:
- RNA Interference
- Antisense RNA
- By Application:
- Genetic Disease
- Cancer
- Infectious Disease
- Neurodegenerative Disorders
- Cardio Metabolic & Renal Disorders
- Ocular Disorders
- Respiratory Disorders
- Skin Disorders
- Others
- By Route of Administration:
- Intravenous Injections
- Intrathecal Injections
- Subcutaneous Injections
- Others
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profile
- Benitec Biopharma Inc.
- Silence Therapeutics
- Ionis Pharmaceuticals, Inc
- Bio-Path Holdings Inc.
- Percheron Therapeutics Limited
- GSK plc
- Olix Pharmaceuticals, Inc.
- Sanofi
- Alnylam Pharmaceuticals, Inc.
- Arbutus Biopharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Technology
- Market Snippet, By Application
- Market Snippet, By Route of Administration
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Promising Innovations in Drug Delivery Systems
- High Manufacturing Cost of RNA Therapeutics
- Untapped Emerging Markets
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Antisense & RNAi Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Economic Impact
5. Antisense & RNAi Therapeutics Market , By Technology, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- RNA Interference
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Antisense RNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Antisense & RNAi Therapeutics Market , By Application, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Genetic Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Infectious Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Neurodegenerative Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Cardio Metabolic & Renal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Ocular Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Respiratory Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Skin Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
7. Antisense & RNAi Therapeutics Market , By Route of Administration, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Intravenous Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Intrathecal Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Subcutaneous Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
8. Antisense & RNAi Therapeutics Market , By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region , 2020-2032,(US$ Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Benitec Biopharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Silence Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ionis Pharmaceuticals, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bio-Path Holdings Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Percheron Therapeutics Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GSK plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Olix Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alnylam Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Arbutus Biopharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
관련자료
